McKesson (NYSE:MCK) Stock Price Expected to Rise, Barclays Analyst Says

McKesson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Barclays raised its McKesson price target to $1,235 from $1,000 and maintained an Overweight rating, implying 13.44% upside. Analysts overall rate the stock “Moderate Buy,” with an average target of $1,054.12.
  • McKesson beat quarterly expectations, reporting EPS of $11.68 versus a $10.72 estimate and revenue of $110.96 billion versus a $109.90 billion estimate; revenue rose 7.5% year over year.
  • MarketBeat previews the top five stocks to own by December 1st.

McKesson (NYSE:MCK - Get Free Report) had its target price boosted by investment analysts at Barclays from $1,000.00 to $1,235.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Barclays's target price would indicate a potential upside of 13.44% from the company's current price.

Several other research analysts also recently issued reports on MCK. Citigroup boosted their price objective on shares of McKesson from $945.00 to $1,000.00 and gave the stock a "buy" rating in a report on Friday, July 24th. Robert W. Baird set a $1,015.00 target price on McKesson in a research report on Thursday, August 6th. Argus lifted their target price on McKesson from $850.00 to $970.00 and gave the stock a "buy" rating in a research report on Thursday, September 3rd. JPMorgan Chase & Co. upped their price target on McKesson from $1,042.00 to $1,255.00 and gave the company an "overweight" rating in a report on Tuesday, November 10th. Finally, TD Cowen upped their price target on McKesson from $1,006.00 to $1,200.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $1,054.12.

Get Our Latest Stock Analysis on McKesson

McKesson Trading Down 1.5%

Shares of MCK stock opened at $1,088.68 on Wednesday. McKesson has a 1 year low of $723.68 and a 1 year high of $1,121.50. The firm's fifty day simple moving average is $963.44 and its 200 day simple moving average is $877.27. The firm has a market capitalization of $125.70 billion, a P/E ratio of 27.99, a price-to-earnings-growth ratio of 1.87 and a beta of 0.27.

McKesson (NYSE:MCK - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating the consensus estimate of $10.72 by $0.96. McKesson had a net margin of 1.12% and a negative return on equity of 202.94%. The firm had revenue of $110.96 billion during the quarter, compared to analysts' expectations of $109.90 billion. During the same period in the prior year, the company earned $9.86 EPS. The business's quarterly revenue was up 7.5% compared to the same quarter last year. Equities research analysts anticipate that McKesson will post 46.16 EPS for the current fiscal year.

Insider Activity at McKesson

In other news, EVP Francisco Fraga sold 650 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $1,102.96, for a total value of $716,924.00. Following the completion of the transaction, the executive vice president directly owned 4,414 shares of the company's stock, valued at approximately $4,868,465.44. This represents a 12.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO B Jr sold 111 shares of the firm's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the transaction, the chief accounting officer owned 521 shares of the company's stock, valued at $464,445.45. This trade represents a 17.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 2,161 shares of company stock worth $2,242,515. Corporate insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of McKesson during the second quarter worth approximately $8,156,743,000. Bank of America Corp DE acquired a new stake in shares of McKesson in the second quarter valued at approximately $998,896,000. Legal & General Group Plc bought a new stake in shares of McKesson in the second quarter valued at approximately $656,566,000. The Manufacturers Life Insurance Company bought a new stake in shares of McKesson in the second quarter valued at approximately $651,462,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of McKesson in the second quarter valued at approximately $599,060,000. 85.07% of the stock is owned by institutional investors.

McKesson Company Profile

(Get Free Report)

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers. The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care. Founded in 1833, McKesson serves customers primarily in the United States and Canada.

Recommended Stories

Analyst Recommendations for McKesson (NYSE:MCK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in McKesson Right Now?

Before you consider McKesson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.

While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines